Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.

@article{Peters2012EvaluationOR,
  title={Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.},
  author={Nathan C Peters and Sylvie Bertholet and Phillip G. Lawyer and M{\'e}lanie Charmoy and Audrey Romano and Fl{\'a}via Lima Ribeiro-Gomes and Lisa W. Stamper and David L Sacks},
  journal={Journal of immunology},
  year={2012},
  volume={189 10},
  pages={4832-41}
}
Numerous experimental Leishmania vaccines have been developed to prevent the visceral and cutaneous forms of Leishmaniasis, which occur after exposure to the bite of an infected sand fly, yet only one is under evaluation in humans. KSAC and L110f, recombinant Leishmania polyproteins delivered in a stable emulsion (SE) with the TLR4 agonists monophosphoryl lipid A or glucopyranosyl lipid A (GLA) have shown protection in animal models. KSAC+GLA-SE protected against cutaneous disease following… CONTINUE READING